srcl-ex106_26.htm

This First Amendment dated as of July 28, 2017 (the or this “Agreement”) to the Note Purchase Agreement referred to below is between Stericycle, Inc., a Delaware corporation (the “Company”), and each of the institutions which is a signatory to this Agreement (collectively, the “Noteholders”).

Whereas, the Company and each of the Noteholders have heretofore entered into the Note Purchase Agreement dated as of October 1, 2015 (the “Note Purchase Agreement”), pursuant to which the Company issued on or about October 1, 2015 (a) $150,000,000 aggregate principal amount of its 2.89% Senior Notes, Series A, due October 1, 2021 (as amended, the “Series A Notes”) and (b) $150,000,000 aggregate principal amount of its 3.18% Senior Notes, Series B, due October 1, 2023 (as amended, the “Series B Notes” and together with the Series A Notes, collectively, the “Notes”);

Whereas, the Company and the Noteholders now desire to amend the Note Purchase Agreement and the Notes in the respects, but only in the respects, hereinafter set forth;

Whereas, all capitalized terms used herein and not defined herein shall have the meaning specified in the Note Purchase Agreement;

Whereas, all requirements of law have been fully complied with and all other acts and things necessary to make this Agreement a valid, legal and binding instrument according to its terms for the purposes herein expressed have been done or performed.

Now, therefore, upon the full and complete satisfaction of the conditions precedent to effectiveness set forth in Section 3.1 hereof, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and each of the Noteholders do hereby agree as follows:

Section 1.1.Section 10.1(a) of the Note Purchase Agreement is hereby amended and restated in its entirety to read as follows:

(i) The Company will not permit the Consolidated Leverage Ratio as of the end of any fiscal quarter of the Company to exceed 3.75 to 1.00; provided that if the Consolidated Leverage Ratio, on a pro forma basis as of any such date and immediately after giving effect to the settlement payment of the MDL Contract Action, is greater than 3.50 to 1.00, the Company may, in its sole discretion, elect to increase the maximum Consolidated Leverage Ratio permitted by this Section 10.1(a)(i) to 4.00 to 1.00 as of the

end of the fiscal quarter in which the settlement payment of the MDL Contract Action occurred and in any subsequent fiscal quarter ending on or prior to September 30, 2018 (the “MDL Period”); provided further in no event shall the elevated ratio permitted by the immediately preceding proviso extend after September 30, 2018. Such election shall be made by the delivery of a written notice by the Company to the holders of Notes making reference to this Section 10.1(a) and notifying the holders of Notes of the Company’s election to increase the maximum Consolidated Leverage Ratio as provided above on or prior to the date of the actual or required delivery of a certificate required under Section 7.2 for the fiscal quarter in which the settlement payment of the MDL Contract Action occurred; and

(ii) If at the end of any fiscal quarter of the Company during the MDL Period the Consolidated Leverage Ratio exceeded 3.75 to 1.00 (an “MDL Leverage Increase”), the per annum interest rate (including any Default Rate, if applicable) otherwise applicable to each series of the Notes as specified in the first paragraph thereof shall be increased by 50 basis points (.50%) (the “MDL Leverage Increased Interest Rate”) from the date of such MDL Leverage Increase to but not including the date that the Consolidated Leverage Ratio is 3.75 to 1.00 or less. The Company shall promptly, and in any event within 10 Business Days, following an MDL Leverage Increase notify the holders of the Notes in writing that an MDL Leverage Increase has commenced and the date of such commencement. Payment of the MDL Leverage Increased Interest Rate shall not constitute a waiver of any Default or Event of Default hereunder.”

Section 1.2.Additional Definitions. Schedule B to the Note Purchase Agreement is hereby amended to insert the following definitions, each in its respective alphabetical order:

“First Amendment” means the First Amendment dated as of July 28, 2017 to this Agreement between the Company and the holders party thereto.

“MDL Contract Action” means the claims made against the Company in In re: Stericycle, Inc., Steri-Safe Contract Litigation, Case No. 13 C 5795, MDL No. 2455 brought in the United States District Court for the Northern District of Illinois Eastern Division.

“Other Note Agreements” means each of the following note purchase agreements among the Company and the holders of notes party thereto: (i) the Note Purchase Agreement dated as of August 18, 2010, (ii) the Note Purchase Agreement dated as of October 22, 2012 and (iii) the Note Purchase Agreement dated as of April 30, 2015, each as amended, restated, joined, supplemented or otherwise modified from time to time.

“Term Loan Agreement” means the Term Loan Credit Agreement dated as of August 21, 2015 by and among the Company, certain Subsidiaries of the Company named therein, Bank of America, N.A., as administrative agent, and the other financial institutions party thereto, as amended, restated, joined, supplemented or otherwise modified from time to time.

Section 1.3.Amended Definitions. Schedule B to the Note Purchase Agreement is hereby amended by amending and restating each of the following definitions in its entirety to read as follows:

“Consolidated EBITDA” means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) the provision for federal, state, local and foreign income taxes payable by the Company and its Subsidiaries for such period, (iii) depreciation and amortization expense, (iv) other non-recurring expenses of the Company and its Subsidiaries reducing such Consolidated Net Income which do not represent a cash item in such period or any future period, (v) non-cash stock compensation expenses of the Company and its Subsidiaries incurred in such period, (vi) up to $45,000,000 in the aggregate of cash charges associated with the settlement of the TCPA Action, (vii) up to $295,000,000 in the aggregate of cash charges associated with the settlement of the MDL Contract Action, and (viii) up to $5,000,000 in the aggregate of cash charges related to legal fees and expenses associated with (x) the MDL Contract Action, (y) the First Amendment and (z) the corresponding amendments to the Bank Credit Agreement, the Term Loan Agreement and Other Note Agreements minus (b) the following to the extent included in calculating such Consolidated Net Income: (i) federal, state, local

and foreign income tax credits of the Company and its Subsidiaries for such period and (ii) all non-cash items increasing Consolidated Net Income for such period; provided, however, that Consolidated EBITDA shall be increased by the amount of Transaction Costs incurred during such period to the extent such amount was deducted in determining Consolidated Net Income for such period. For purposes of calculating Consolidated EBITDA for any period of four consecutive quarters, if during such period the Company or any Subsidiary shall have made any Acquisition or disposed of any Person or of all or substantially all of the operating assets of any Person, Consolidated EBITDA for such period shall be calculated after giving pro forma effect thereto as if such transaction occurred on the first day of such period.

“Increased Interest Rate” means the occurrence of a Primary Increased Interest Rate or MDL Leverage Increased Interest Rate, as applicable.

Section 2.1.To induce the Noteholders to execute and deliver this Agreement, the Company represents and warrants (which representations shall survive the execution and delivery of this Agreement) to the Noteholders that:

(a)this Agreement has been duly authorized, executed and delivered by the Company and, upon execution and delivery thereof by the parties hereto, this Agreement constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors’ rights generally;

(b)the Note Purchase Agreement, as amended by this Agreement, constitutes the legal, valid and binding obligation, contract and agreement of the Company enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles relating to or limiting creditors’ rights generally;

(c)the execution, delivery and performance by the Company of this Agreement (i) has been duly authorized by all requisite corporate actions on the part of the Company, (ii) does not require the consent or approval of any governmental or regulatory body or agency, and (iii) will not (A) violate (1) any provision of law, statute, rule or regulation applicable to the Company or its certificate of incorporation or bylaws, (2) any order of any court or any rule, regulation or order of any other agency or government binding upon it, or (3) any provision of any material indenture, agreement or other instrument to which it is a party or by which its properties or assets are or may be bound, or (B) result in a breach or constitute (alone or with due notice or lapse of time or

both) a default under any indenture, agreement or other instrument referred to in clause (iii)(A)(3) of this Section 2.1(c);

(d)as of the date hereof and after giving effect to this Agreement, no Default or Event of Default has occurred which is continuing; and

(e)the representations and warranties contained in Section 5 of the Note Purchase Agreement are true and correct in all material respects with the same force and effect as if made by the Company on and as of the date hereof, except to the extent that any such representation or warranty expressly relates to an earlier date.

Section 3.1.The amendments to the Note Purchase Agreement set forth herein shall not become effective until, and shall become effective when (the “Effective Date”), each of the following conditions shall have been satisfied:

(a)executed counterparts of this Agreement, duly executed by the Company and the holders of 51% in principal amount of the outstanding Notes, shall have been delivered to the Noteholders;

(b)copies of a favorable written opinion of counsel to the Company addressed to each of the Noteholders as to matters set forth in Section 2.1(a) through (c) hereof (provided that the opinion regarding Section 2.1(c)(iii)(3) will relate to the Other Note Purchase Agreements, Bank Credit Agreement and the Term Loan Agreement (as defined in the Note Purchase Agreement after giving effect to this Agreement)), in form and substance satisfactory to the Noteholders, shall have been delivered to the Noteholders;

(c)the representations and warranties of the Company set forth in Section 2 hereof shall be true and correct on and with respect to the date hereof, and the execution and delivery by the Company of this Agreement shall constitute certification by the Company of the same;

(d)the Company shall have paid a fee to each holder of Notes equal to five basis points (.05%) on the outstanding principal amount of Notes held by each such holder of Note as of the Effective Date;

(e)the Company shall have paid the fees and expenses of Chapman and Cutler LLP, special counsel to the Noteholders, incurred in connection with the negotiation, preparation, approval, execution and delivery of this Agreement for which an invoice has been provided;

(f)the Company shall have delivered copies of an amendment to each of the Bank Credit Agreement and the Term Loan Agreement (as defined in the Note Purchase Agreement after giving effect to this Agreement), each amending such agreements in

substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement; and

(g)the Company shall have delivered copies of an amendment to each of the Other Note Agreements (as defined in the Note Purchase Agreement after giving effect to this Agreement) between the Company and the purchasers named therein, each amending such agreements in substance consistent with the amendments to the Note Purchase Agreement as contemplated by this Agreement.

Upon receipt and satisfaction of all of the foregoing, such amendments shall become effective.

Section 4.1.This Agreement shall be construed in connection with and as part of the Note Purchase Agreement, and except as modified and expressly amended by this Agreement, all terms, conditions and covenants contained in the Note Purchase Agreement are hereby ratified and confirmed and shall be and remain in full force and effect.

Section 4.2.Any and all notices, requests, certificates and other instruments, including the Notes, may refer to the “Note Purchase Agreement” or the “Note Purchase Agreement dated as of October 1, 2015” without making specific reference to this Agreement, but nevertheless all such references shall be deemed to include this Agreement unless the context shall otherwise require.

Section 4.3.The descriptive headings of the various Sections or parts of this Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions hereof.

Section 4.4.This Agreement shall be governed by and construed in accordance with New York law excluding choice‑of‑law principles of the law of New York that would require the application of the laws of jurisdiction other than New York.

Section 4.5.This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original, but all together only one agreement. This Agreement, together with the Note Purchase Agreement (as amended hereby) and the Notes, constitutes the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.

In Witness Whereof, the parties hereto have executed this Agreement as of the Effective Date.

Stericycle, Inc.

By		/s/ Daniel V. Ginnetti
	Name:	Daniel V. Ginnetti
	Title:	Chief Financial Officer, Executive Vice
		President

Metropolitan Life Insurance Company

General American Life Insurance Company
by	Metropolitan Life Insurance Company, Its Investment Manager

By		/s/ John Wills
	Name:	John Wills
	Title:	Senior Vice President & Managing Director

Brighthouse Life Insurance Company
by	MetLife Investment Advisors, LLC, Its Investment Manager

Erie family Life Insurance Company
by	MetLife Investment Advisors, LLC, Its Investment Manager

By		/s/ Judith A. Gulotta
	Name:	Judith A. Gulotta
	Title:	Managing Director

The Northwestern Mutual Life Insurance Company

by	Northwestern Mutual Investment Management Company, LLC, Its Investment Adviser

By		/s/ David A. Barras
	Name:	David A. Barras
	Title:	Managing Director

The Northwestern Mutual Life Insurance Company for its Group Annuity Separate Account

By		/s/ David A. Barras
	Name:	David A. Barras
	Title:	Its Authorized Representative

New York Life Insurance Company

By		/s/ A. Post Howland
	Name:	A. Post Howland
	Title:	Vice President

New York Life Insurance And Annuity Corporation

by	NYL Investors LLC Its Investment Manager

By		/s/ A. Post Howland
	Name:	A. Post Howland
	Title:	Vice President

New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 3)

by	NYL Investors LLC Its Investment Manager

By		/s/ A. Post Howland
	Name:	A. Post Howland
	Title:	Vice President

The Bank of New York Mellon, a banking corporation organized under the laws of New York, not in its individual capacity but solely as trustee under that certain trust agreement dated as of July 1^st, 2015 between New York Life Insurance Company (U.S.A.), as Beneficiary, John Hancock Life Insurance Company of New York, as Beneficiary, and the Bank of New York Mellon, as Trustee

by	New York Life Insurance Company, its Attorney-in-Fact

By		/s/ A. Post Howland
	Name:	A. Post Howland
	Title:	Vice President

State Farm Life Insurance Company

By		/s/ Julie Hoyer
	Name:	Julie Hoyer
	Title:	Investment Executive

By		/s/ Jeffrey Attwood
	Name:	Jeffrey Attwood
	Title:	Investment Professional

State Farm Life and Accident Assurance Company

By		/s/ Julie Hoyer
	Name:	Julie Hoyer
	Title:	Investment Executive

By		/s/ Jeffrey Attwood
	Name:	Jeffrey Attwood
	Title:	Investment Professional

Nationwide Life Insurance Company

By		/s/ Jason Comisar
	Name:	Jason Comisar
	Title:	Authorized Signatory

Thrivent Financial For Lutherans

By		/s/ Martin Rosucker
	Name:	Martin Rosucker
	Title:	Managing Director

Principal Life Insurance Company

By:	Principal Global Investors, LLC, a Delaware limited liability company, its authorized signatory

By		/s/ Eldwin A. Nichols
	Name:	Eldwin A. Nichols
	Title:	Counsel

By		/s/ Colin Pennycooke
	Name:	Colin Pennycooke
	Title:	Counsel

State of Wisconsin Investment Board

By		/s/ Christopher P. Prestigiacomo
	Name:	Christopher P. Prestigiacomo
	Title:	Portfolio Manager

By:	Fort Washington Investment Advisors, as investment adviser for Auto-Owners Insurance Company

By		/s/ Douglas E. Kelsey
	Name:	Douglas E. Kelsey
	Title:	VP – Private Placements

By		/s/ Brendan White
	Name:	Brendan White
	Title:	Co-Chief Investment Officer

By:	Fort Washington Investment Advisors, as investment adviser for Auto-Owners Life Insurance Company

By		/s/ Douglas E. Kelsey
	Name:	Douglas E. Kelsey
	Title:	VP – Private Placements

By		/s/ Brendan White
	Name:	Brendan White
	Title:	Co-Chief Investment Officer

American United Life Insurance Company

By		/s/ Michael I. Bullock
	Name:	Michael I. Bullock
	Title:	VP – Private Placements

The State Life Insurance Company

By:	American United Life Insurance Company
Its:	Agent

By		/s/ Michael I. Bullock
	Name:	Michael I. Bullock
	Title:	VP – Private Placements

Ameritas Life Insurance Corp.
Ameritas Life Insurance Corp. of New York

By	Ameritas Investment Partners, Inc., as Agent

By		/s/ Tina Udell
	Name:	Tina Udell
	Title:	Vice President & Managing Director

PHL Variable Insurance Company

By		/s/ Christopher M. Wilkos
	Name:	Christopher M. Wilkos
	Title:	Vice President

Woodmen of the World Life Insurance Society

By		/s/ Dean Holdsworth
	Name:	Dean Holdsworth
	Title:	Director Mortgage Loan/RE

Southern Farm Bureau Life Insurance Company

By		/s/ David Divine
	Name:	David Divine
	Title:	Senior Portfolio Manager

Physicians Mutual Insurance Company

by	Prudential Private Placement Investors, L.P. (as Investment Advisor)

by	Prudential Private Placement Investors, Inc. (as its General Partner)

By		/s/ Physicians Mutual Insurance Company
	Name:
	Title:	Vice President